AIM ImmunoTech’s Phase 2 Ampligen-Imfinzi Study Reports Promising Progress in Pancreatic Cancer
Market Chameleon (Mon, 8-Jun 11:44 AM)
Ampligen’s 100% Survival Rate in Ebola Mouse Model Puts Spotlight on AIM ImmunoTech’s New Opportunity
Market Chameleon (Thu, 28-May 11:55 AM)
AIM ImmunoTech Highlights Ampligen’s Ebola Potential After WHO Emergency—Pre-Clinical Data Shows 100% Survival in Study
Market Chameleon (Wed, 27-May 11:05 AM)
